[ARS] GILEAD SCIENCES, INC. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

ARS

Rhea-AI Filing Summary

Analyzing...

03/20/2026 - 04:01 PM

ARS - GILEAD SCIENCES, INC.

ARS Filing - GILEAD SCIENCES, INC.

This filing is available as a PDF document.

Filing Type: ARS

Company: GILEAD SCIENCES, INC. (GILD)

Acceptance Date: 2026-03-20T16:01:42.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Gilead Sciences Inc

NASDAQ:GILD

View GILD Stock Overview →

GILD Rankings

#72 Ranked by Market Cap

N/A Ranked by Dividends

GILD Latest News

Mar 2, 2026

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

Feb 25, 2026

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

Feb 23, 2026

Gilead Sciences to Present at Upcoming Investor Conferences

Feb 23, 2026

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

Feb 17, 2026

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

GILD Latest SEC Filings

Mar 20, 2026

[DEF 14A] GILEAD SCIENCES, INC. Definitive Proxy Statement

Mar 17, 2026

[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity

Mar 17, 2026

[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity

Mar 16, 2026

[144] GILEAD SCIENCES, INC. SEC Filing

Mar 16, 2026

[144] GILEAD SCIENCES, INC. SEC Filing

GILD Stock Data

Market Cap 175.18B

Float 1.24B

Industry Drug Manufacturers - General

Sector Biological Products, (no Diagnostic Substances)

Website Link

Country United States

City FOSTER CITY